Participants who took 600 milligrams of the common painkiller daily for at least two years had a 63 percent lower rate of colorectal cancer than those who took a placebo, according to the study led by John Burn, a professor of clinical genetics at Newcastle University in England. The participants all were carriers of Lynch Syndrome, a genetic condition that predisposes a person to developing certain cancers.
Link: http://www.businessweek.com/news/2011-10-28/aspirin-reduces-bowel-cancer-risk-by-63-percent-in-study.html